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Background: Platelet-activating factor (PAF) is a highly potent phospholipid mediator responsible for the
life-threatening manifestations of anaphylaxis. PAF acetylhydrolase (PAF-AH) inactivates PAF and protects against
severe anaphylaxis whereas deficiency of PAF-AH predisposes to severe or fatal anaphylaxis. Determinants of PAF-AH
activity have not been studied in patients with peanut allergy.
Objectives: To determine whether plasma PAF-AH activity in patients with peanut allergy is related to formation of
circulating complexes with apolipoprotein B (apoB) the main surface protein on low density lipoprotein particles.
Methods: Plasma PAF-AH activity and apoB concentrations were measured in 63 peanut allergic patients (35 boys, 28
girls, ages 2 – 19 years). ApoB concentration was measured immunoturbidimetrically using goat anti-human apoB. The
correlation between PAF-AH activity and apoB concentration was determined.
Results: A positive correlation was found between PAF-AH activity and apoB concentration (r2 = 0.59, P < 0.0001).
Conclusion: In peanut allergic patients, PAF-AH activity strongly correlates with apoB concentration, suggesting the
presence of circulating PAF-AH- lipoprotein complexes.
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Deficiency of platelet activating factor acetylhydrolase
(PAF-AH) predisposes to severe or fatal anaphylaxis.
PAF-AH correlates with apolipoprotein B in peanut
allergic patients, suggesting that formation of PAF-AH-
lipoprotein complexes is an important determinant of
PAF-AH activity.Introduction
Platelet-activating factor (PAF) is one of the most potent
lipid messengers involved in inflammatory events. PAF
has been implicated in mediating the life-threatening
manifestations of anaphylaxis including hypotension,
increased vascular permeability, and severe broncho-
constriction [1,2]. The association of PAF with severe* Correspondence: vadasp@smh.ca
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unless otherwise stated.or fatal anaphylaxis has been observed in both animal
models and in humans. PAF receptor antagonists pro-
tected against fatal anaphylaxis in experimental animals
[3,4]. PAF receptor knockout mice were resistant to
fatal anaphylaxis as compared to wild type mice [5]. In
humans, PAF levels correlated more strongly with ana-
phylaxis severity than did histamine or tryptase [6,7]. In
human vascular smooth muscle cells, epinephrine blocked
PAF mediated signaling, likely by phosphorylation of the
PAF receptor [8].
Serum PAF concentrations are rigorously controlled by
tight regulation of biosynthesis and degradation. Cells
synthesize and secrete PAF de novo only when stimulated.
De-acetylation of PAF at the sn-2 position terminates the
biologic activity of PAF, with formation of the inactive
metabolite, lysoPAF [9]. The de-acetylation reaction is
catalyzed by PAF acetylhydrolase (PAF-AH), a calcium-
independent phospholipase A2 [10]. PAF-AH activity is
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in sera of PAF-AH deficient persons [6,11]. Conversely,
increasing concentrations of PAF-AH correlate with
more rapid inactivation of PAF [6]. Patients deficient in
PAF-AH have been shown to be at increased risk of
severe or fatal anaphylaxis, although the mechanisms
regulating PAF-AH activity in patients at risk for fatal
anaphylaxis have not yet been defined [6].
The circulating form of PAF-AH is also known as
lipoprotein-associated phospholipase A2. In human plasma,
70% of PAF-AH circulates in fully active form as a complex
with low density lipoprotein (LDL) and the remainder
in high density lipoproteins (HDL) [12]. Plasma PAF-AH
concentration directly correlates with LDL cholesterol
concentrations in male subjects [13], such that changes in
LDL concentration are reflected by corresponding changes
in PAF-AH concentration. The catalytic activity of PAF-AH
is regulated by its association with LDL, as lowering LDL
in plasma increases the half-life of PAF [13]. The half-
life of PAF is also prolonged in patients with abetali-
poproteinemia, a condition characterized by deficiency of
apolipoprotein-containing lipoproteins, including LDL
[13]. Drugs that lower LDL levels lower PAF-AH activity
as well. For example, rabbits treated with simvastatin
for two months showed decreased PAF-AH activity as
compared with control rabbits [14]. Although PAF-AH
predominantly circulates in the blood associated with LDL
in normolipidemic individuals, the relative proportion of
PAF-AH associated with LDL and HDL can be affected
by various factors [13]. The relationship between PAF-AH
activity and LDL concentrations has not been studied in
patients with a history of peanut allergy.
Apolipoprotein B (apoB) is complexed mainly with LDL
and is a good surrogate measure of LDL concentration
[15]. Generally, more than 90% of plasma apoB is on LDL
particles (the remainder on LDL precursors). Each LDL
precursor particle has exactly one molecule of apoB on its
surface, which remains there during shrinkage to an LDL
particle [16]. We undertook this study to investigate
whether there is a correlation between PAF-AH activity




Apolipoprotein B concentrations and PAF-AH activity
were measured in 63 children with peanut allergy (35 boys
and 28 girls; mean age, 6.5 ± 3.9 years; range 2–19 years).
These children had previous allergic reactions to peanut
characterized only by urticaria and/or angioedema with
positive skin tests to peanut protein of ≥ 8 mm wheal
diameter and/or peanut-specific IgE ≥ 14 kU/L.
The demographics and diagnostic criteria for this patient
cohort were reported previously [6]. Informed consent wasobtained from all patients or their parents or guardians.




3-phosphoholine, 499.5 Gbq/mmol) was purchased from
NEN Life Science Products (Boston, MA). Unlabelled PAF
and lyso-PAF were from BIOMOL (Brockville, Ontario).
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
egg yolk phosphatidylcholine, pefabloc (4-2-[aminoethyl]
benzenesulfonyl fluoride) and apolipoprotein-B kit were
obtained from Sigma (Oakville, Ontario). Pre-coated TLC
plates SILICA GEL 60 (layer thickness 0.25 mm, 20 ×
20 cm) were from Merck, Germany. All other chemicals
were from Sigma.
Measurement of Apolipoprotein-B concentrations
Plasma PAF-AH activity has been shown to correlate
strongly with the plasma concentration of low density li-
poproteins (LDL) [10]. PAF-AH activity was measured
as a function of apoB concentration. Human apoB con-
centration was measured immunoturbidimetrically using
goat anti-human apoB (Sigma), which forms an insoluble
complex resulting in turbidity of the assay mixture. Tur-
bidity was measured spectrophotometrically at 340 nm.
The concentration of apoB in the samples was determined
from a calibration curve using multiple-level apoB calibra-
tors (Sigma) at 5 different concentrations, ranging from
0–182 mg/dl.
Measurement of PAF-AH activity
PAF-acetylhydrolase activity was measured according to
the method of Miwa et al [2] as modified by Vadas et al [6].
Results
PAF-AH and apoB concentrations in patients with peanut
allergy
PAF-AH activity and apoB concentrations were measured
in 63 peanut allergic patients. The relationship between
PAF-AH activity, peanut-specific IgE levels and apoB
concentrations is shown in Table 1. PAF-AH activities
were plotted as a function of apoB concentrations. Plasma
PAF-AH activity was strongly correlated with the plasma
concentrations of apoB (r2 = 0.59, P < 0.0001) (Figure 1).
Discussion
Recently, we reported that in patients with acute allergic
reactions, blood PAF levels correlated with severity of
anaphylaxis. Patients with the highest levels of circulating
PAF had more severe reactions and, conversely, those with
lowest PAF levels had least severe reactions [6]. PAF-AH
activity correlated inversely with PAF levels and patients
with the lowest levels of PAF-AH were at highest risk of
Table 1 PAF-AH, peanut-specific IgE and ApoB concentra-






Mean 25.18 110.5 50.51
Standard deviation 5.67 270.60 17.17
Standard error 0.7150 34.09 2.163
Lower 95% CI of mean 23.75 42.39 46.18
Upper 95% CI of mean 26.61 178.70 54.83
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with severe anaphylaxis vs patients with mild – moderate
reactions was 27.0 (95% CI, 4.2-175.5; 2 tailed P = 0.00005
for uncorrected Chi-square) [17]. An odds ratio of 27.0
suggests that patients with the lowest levels of PAF-AH
activity were 27.0 times more at risk of severe or fatal ana-
phylaxis, as compared to patients with normal levels of
PAF-AH activity. These and other studies [18] suggest that
PAF-AH deficiency predisposes to severe anaphylaxis.
PAF is a potent pro-inflammatory phospholipid messen-
ger which acts via a trans-membrane G-protein coupled
PAF receptor [11]. The production of PAF is tightly regu-
lated by both synthetic and degradative processes. Whereas
synthesis of PAF in activated cells involves at least 2 en-
zymes, an arachidonate-specific phospholipase A2 (PLA2)
and acetyl-CoA-lyso-PAF acetyltransferase, the degradation
of PAF to the biologically inactive form, lyso-PAF, is accom-
plished by the enzyme PAF-AH. The most likely function
of PAF-AH may be that of a safety mechanism to limit the
levels of PAF [19].
In contrast to proinflammatory phospholipases [20,21],
PAF-AH is an anti-inflammatory phospholipase that oc-
curs as a plasma isoform complexed mainly with LDL.
In a cohort of 240 normolipidemic individuals, plasma
PAF-AH activity was strongly correlated with the plasma
concentration of LDL [22]. Among normolipidemic indi-



















Figure 1 Scatterplot of PAF-AH activity and apolipoprotein
B concentrations.in proportionate decreases in plasma PAF-AH activity
and LDL concentrations [22,23]. Removal of LDL from
the circulation may determine the clearance rate of
PAF-AH, modulating the activity of PAF-AH in blood,
and thereby influencing the level of PAF [22].
In this study, our aim was to investigate whether PAF-
AH activity correlates with apoB, the main surface protein
on LDL particles, in patients with peanut allergy. We did
find a linear relationship between serum PAF-AH and
apoB concentrations throughout the range of PAF-AH
activities, in a pediatric patient population. Complex
formation with lipoproteins, especially LDL, may, there-
fore, be an important determinant of PAF-AH activity.
Dietary or pharmacologic strategies to lower LDL may
have the unintended consequence of altering PAF-AH
activity. In particular, lowering LDL levels pharmaco-
logically in patients at risk for anaphylaxis may lower
PAF-AH activity in these patients as well, inadvertently
leading to an increased risk of severe or fatal anaphyl-
axis. It remains to be seen if the results reported for a
pediatric age group can be extended to adult patients
who are most likely to be using lipid lowering drugs. A
study of the relationship between use of lipid lowering
drugs to severity of anaphylaxis is currently in progress.
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